|
Search
Collections
Benchmarks
Upload document
Product
Ocrevus
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 clinical trial
1 indication
Indication
Secondary-progressive Multiple Sclerosis
Clinical trial
Open-label, Single-blind, Observational, Comparative, Prospective, 36-month, Longitudinal, Controlled Study to Assess Efficacy of Siponimod (Mayzent®) on Microglia in Patients With Active Secondary Progressive Forms of Multiple Sclerosis
Status: Completed
, Estimated PCD: 2023-06-01